Dr. Alison Humbles brings over 20 years of international experience in the biopharmaceutical and biotechnology industries, spanning research, development, and strategic programme management. She has held senior scientific and leadership positions across global organisations, including Roche, where she served as Disease Area Lead for Respiratory, and MedImmune (now part of AstraZeneca), leading translational programmes in inflammation, respiratory disease, and immunology. Her early research career included work at the Children’s Hospital and Harvard Medical School in Boston, contributing to groundbreaking studies in inflammatory biology. She has contributed to multiple global drug-development pipelines and advised emerging biotech ventures, including ENA Respiratory, on antiviral host-defence strategies. As Senior Portfolio Manager for the ARC Hub for Therapeutics, she’s oversees strategic research portfolios, builds partnerships, and drives collaboration across academia, funders, and industry to accelerate the development of next-generation therapies.
Innovation Training for ARC Hub for Therapeutics Translational Researchers
To complement excellence in scientific research, successful commercialisation requires research teams to have a strong understanding of their target markets, the specific problems their technologies address, the competitive landscape, and the ability to...
